论文部分内容阅读
对建德市ＨＦＲＳⅠ型灭活疫苗随机对照现场随访３９个月，采集免前和免后双份血清４０１人，检测ＩＦＡＴ和ＭＣＰＥＮＴ。免前ＩＦＡ抗体阴性者３６９人，免后ＩＦＡ阳性率和几何平均滴度分别是１５．９９％和１．６６，免后ＭＣＰＥＮＴ阳性率和几何平均滴度分别是７．３２％和１．１２；免前ＩＦＡ抗体阳性者３２人，免后ＩＦＡ阳性率和几何平均滴度分别是６８．７５％和１５．３５；疫苗保护发病效果为１００％，且对Ⅱ型病例也有保护作用。疫苗的中期保护发病效果较好，免后３９个月抗体水平下降幅度很大。提示疫苗的免疫原性评价应以基础和加强接种后２～３周的抗体水平为主要指标。
A randomized controlled trial of HFRS type I in Jiande City was followed up for 39 months. Two hundred and seventy-two serum samples were collected before and after immunization. IFAT and MCPENT were detected. 369 without pre-IFA antibody negative, IFA-positive rate and geometric mean titer were 15.99% and 1.66, respectively. The post-avoidance MCPENT positive rate and geometric mean titer were 7.32% and 1.12 ; 32 patients without pre-IFA antibody positive rate and geometric mean titer of IFA after vaccination were 68.75% and 15.35 respectively; the incidence of vaccine protection was 100%, and the protective effect was also observed in type II patients. Vaccination is better in the mid-term protection, 39 months after the antibody level dropped significantly. Prompt vaccine immunogenicity assessment should be based on and strengthen the vaccination 2 to 3 weeks after the antibody level as the main indicator.